Corcept CDO exercises 8,233 options, sells shares

Corcept Therapeutics’ Chief Development Officer William Guyer exercised 8,233 stock options and sold the resulting shares.

Rhea-AI Filing Summary

Corcept Therapeutics’ Chief Development Officer William Guyer exercised 8,233 stock options and sold the resulting shares. On March 4, 2026, he exercised options for 8,233 shares of common stock at an exercise price of $21.65 per share and then sold 8,233 shares in the open market at a weighted average price of $35.9949 per share, with individual sale prices ranging from $35.97 to $36.05. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. After these transactions, Guyer held 2,231 shares of common stock directly, as well as options and restricted stock awards, including 224 and 498 shares underlying unvested restricted stock awards that vest on the one-year anniversaries of their respective grant dates, subject to specified conditions.

Insider Trade Summary

Exercise and Sale: 8,233 shares ($118K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Guyer William

Role Chief Development Officer

Sold 8,233 shs ($296K)

Approx. gross sale proceeds $296K

Approx. exercise cost $178K

Approx. pre-tax spread $118K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	8,233	$0.00	$0.00
Exercise	Common Stock	8,233	$21.65	$178K
Sale	Common Stock	8,233	$35.9949	$296K

Holdings After Transaction: Stock Option (right to buy) — 221,767 contracts (Direct); Common Stock — 2,231 shares (Direct)

Footnotes (4)

1. F1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. F4. Fully exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Corcept Therapeutics (CORT) executive William Guyer report in this Form 4?

William Guyer reported exercising 8,233 stock options and selling 8,233 common shares. The options were exercised at $21.65 per share, and the shares were sold at a weighted average price of $35.9949 per share in open-market transactions.

How many Corcept Therapeutics (CORT) shares did William Guyer sell and at what price?

He sold 8,233 shares of Corcept Therapeutics common stock. The reported weighted average sale price was $35.9949 per share, with individual sale prices ranging from $35.97 to $36.05 per share, all executed in open-market or private transactions.

Were William Guyer’s Corcept (CORT) stock sales under a 10b5-1 plan?

Yes. The filing states the transaction was made under a Rule 10b5-1 trading plan adopted on November 27, 2024. Such plans allow insiders to pre-schedule trades, helping separate personal trading decisions from later nonpublic information.

How many Corcept Therapeutics (CORT) shares does William Guyer own after this Form 4 transaction?

After the reported trades, Guyer directly held 2,231 shares of Corcept common stock. He also holds options and restricted stock awards, including 224 and 498 unvested restricted shares that are scheduled to vest on their one-year grant anniversaries.

What option exercise did William Guyer report for Corcept Therapeutics (CORT)?

He reported exercising stock options covering 8,233 shares of Corcept common stock. The options were exercised at an exercise price of $21.65 per share and were described in the filing as fully exercisable at the time of the transaction.

What unvested restricted stock awards does William Guyer hold in Corcept (CORT)?

The filing notes 224 shares from a December 1, 2025 grant and 498 shares from a March 2, 2026 grant remain unvested. All those restricted shares vest on the one-year anniversaries of their grant dates if specified service or related conditions are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		8,233	A	$21.65	10,464(1)	D
Common Stock	03/04/2026		S(2)		8,233	D	$35.9949(3)	2,231(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.65	03/04/2026		M			8,233	(4)	09/01/2031	Common Stock	8,233	$0.00	221,767	D

Explanation of Responses:

1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.